Citations

Showing 10 of 108094 citations.

MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice
Chen, Yang , Nikolaev, Viacheslav O. , Naro, Fabio , Pellegrini, Manuela , Cardarelli, Silvia , Ma, Xiao , Lee, Hon-Chi , Burnett, John C. , Iyer, Seethalakshmi R., Nikolaev, Viacheslav O , Ma, Xiao , Iyer, Seethalakshmi

Mayo Clinic

Hypertension | July 13, 2022 | Volume: 79 | Issue: 8 | Pages: 1702-1712

10.1161/hypertensionaha.121.18906 | PMID 35674049 Get It

Background: Aldosterone is a critical pathological driver for cardiac and renal diseases. We recently discovered that mutant atrial natriuretic peptide (MANP), a novel atrial natriuretic peptide (ANP) analog, possessed more potent aldosterone inhibitory action than ANP in vivo. MANP and natriuretic peptide (NP)-augmenting therapy sacubitril/valsartan are under investigations for human hypertension treatment. Understanding the elusive mechanism of aldosterone inhibition by NPs remains to be a priority. Conflicting results were reported on the roles of the pGC-A (particulate guanylyl cyclase A receptor) and NP clearance receptor in aldosterone inhibition. Furthermore, the function of PKG (protein kinase G) and PDEs (phosphodiesterases) on aldosterone regulation are not clear. Methods: In the present study, we investigated the molecular mechanism of aldosterone regulation in a human adrenocortical cell line H295R and in mice. Results: We first provided evidence to show that pGC-A, not NP clearance receptor, mediates aldosterone inhibition. Next, we confirmed that MANP inhibits aldosterone via PDE2 (phosphodiesterase 2) not PKG, with specific agonists, antagonists, siRNA silencing, and fluorescence resonance energy transfer experiments. Further, the inhibitory effect is mediated by a reduction of intracellular Ca2+ levels. We then illustrated that MANP directly reduces aldosterone synthase CYP11B2 (cytochrome p450 family 11 subfamily b member 2) expression via PDE2. Last, in PDE2 knockout mice, consistent with in vitro findings, embryonic adrenal CYP11B2 is markedly increased. Conclusions: Our results innovatively explore and expand the NP/pGC-A/3',5', cyclic guanosine monophosphate (cGMP)/PDE2 pathway for aldosterone inhibition by MANP in vitro and in vivo. In addition, our data also support the development of MANP as a novel ANP analog drug for aldosterone excess treatment.
New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease
Crosby, Sheena , Schuh, Michael J. , Becker, Michelle , Ivanov, Marina, Caldera, Freddy , Farraye, Francis A. , Caldera, Freddy , Farraye, Francis A

Mayo Clinic

Inflammatory Bowel Diseases | July 13, 2022 | Volume: 29 | Issue: 4 | Pages: 661-664

10.1093/ibd/izac150 | PMID 35830419 Get It

AbstractPatients with inflammatory bowel disease (IBD) are at a high risk of developing invasive pneumococcal infection both before and after they are diagnosed. The Advisory Committee on Immunization Practices now endorses use of 2 new pneumococcal conjugate vaccines, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20), for patients who have never received a pneumococcal conjugate vaccine or those with unknown vaccination history. Previous studies have shown that pneumococcal vaccination can decrease the risk of developing severe pneumococcal disease; therefore, it is important that patients with IBD receive pneumococcal vaccination. This report aims to inform clinicians who care for patients with IBD about the changes in immunization practices, as it pertains to pneumococcal vaccination and provides appropriate direction on administering vaccination series.
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Weaver, Kimberly N. , Zhang, Xian , Dai, Xiangfeng , Chen, Wenli , Watkins, Runa , Adler, Jeremy, Dubinsky, Marla C. , Kastl, Arthur , Bousvaros, Athos, Strople, Jennifer , Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Craig, Riley, Hernandez, Cristian, Boccieri, Margie , Firestine, Ann M. , Chun, Kelly , Long, Millie D. , Cross, Raymond , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Inflammatory Bowel Diseases | July 13, 2022 | Volume: 29 | Issue: 3 | Pages: 483-486

10.1093/ibd/izac138 | PMID 35830416 Get It

Lay SummaryWe demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.
Use of MEDEVAC Resources in Austere Settings: Paget–Schroetter in the Deployed Environment
Huang, Michelle L, Gerling, Kimberely A, White, Joseph M., Koelling, Erin, O'Donnell, Mary Teresa , Rasmussen, Todd E.

Mayo Clinic

Military Medicine | July 13, 2022 | Volume: 188 | Issue: 11-12 | Pages: 3683-3686

10.1093/milmed/usac194 | PMID 35830418 Get It

ABSTRACT Medical evacuation (MEDEVAC) from a combat zone requires complex decision-making and coordination of assets. A MEDEVAC helicopter team transports not only battle-injured patients but also patients with urgent non-battle-related medical diagnoses from extremely remote locations and are at the mercy of terrain, weather, and enemy contact. The military represents a young population particularly susceptible to venous thoracic outlet syndrome (vTOS) given the rigorous physical activity demands. Current literature supports immediate anticoagulation and surgical decompression within 14 days of diagnosis of vTOS to prevent long-term morbidity. Presented is a case of service member with vTOS presenting at an extremely remote military clinic who underwent a prompt evacuation ∼7,000 miles utilizing rotary-wing transport, followed by three to four more fixed-wing flights to a military treatment facility in the United States. Immediate recognition and ultrasound of this patient to confirm vTOS upon presentation and effective communication to non-medical military commanders and the receiving medical personnel at each Echelon was necessary to ensure an expedited evacuation. The surgeons treating this patient recommend prompt evacuation of deployed service members with suspected vTOS, venogram at the Role 3 if ultrasound is inconclusive, anticoagulation, and return to a Role 4 CONUS facility for definitive surgical management within 14 days. This case is an example of the efficiency of the military MEDEVAC system on a global scale, ensuring optimum medical care for all service members deployed.
Neuro-Ophthalmic Literature Review
Bellows, David A., Chen, John J. , Cheng, Hui‐Chen , MacIntosh, Peter W., Vaphiades, Michael S., Chen, John J , Chan, Noel C. Y. , Zhang, Xiaojun

Mayo Clinic

Neuro-Ophthalmology | July 13, 2022 | Volume: 46 | Issue: 4 | Pages: 275-281

10.1080/01658107.2022.2082199 Get It

Chest wall resection for breast cancer: 21st century Mayo clinic experience
Durgan, Diane M., Thomas, Mathew , Pockaj, Barbara A. , McLaughlin, Sarah A. , Casey, William J., Vijayasekaran, Aparna , Wigle, Dennis A. , Cheville, John C. , Tonneson, Jennifer E., Jakub, James W. , De La Cruz Ku, Gabriel, Wigle, Dennis, Tonneson, Jennifer, Hoskin, Tanya L. , Jakub, James W , Thomas, Mathew , Ku, Gabriel De la Cruz

Mayo Clinic

Journal of Surgical Oncology | July 13, 2022 | Volume: 126 | Issue: 6 | Pages: 962-969

10.1002/jso.27014 | PMID 35830290 Get It

AbstractBackgroundWe hypothesized full‐thickness chest wall resection (FTCWR) with advanced surgical techniques and modern systemic therapy is safe, provides local control, and good overall survival.MethodsRetrospective review of FTCWR (including rib or part of sternum) for breast cancer between 2000 and 2020. Primary endpoints included 90‐day morbidities and all‐cause mortality. Secondary endpoints were loco‐regional and distant recurrence, DFS and overall survival (OS).ResultsA total of 35 patients met the criteria. 34 FTCWR were for recurrence and the median time to chest wall recurrence was 6 years. Tumor subtype was triple‐negative in 51% and the remainder HR+ Her2−. 58% were palliative resections. FTCWR included rib(s) in 89% and portion of sternum in 57%; 94% required reconstruction and 80% were R0 resections. There were no 90‐day mortalities. Overall morbidity was 10/35(28%). 17(49%) patients received neoadjuvant systemic therapy for their recurrence and three received neoadjuvant radiation. Adjuvant treatment included chemotherapy (8), endocrine therapy (3), and both (8). Ten patients (28%) received adjuvant radiation. The Median follow‐up was 31 months and there were 6 (17%) loco‐regional and 7 (20%) distant recurrences. OS was 86% and 67% at 1 and 3 years, respectively.ConclusionFTCWR was associated with low morbidity, mortality, recurrence rates, and good OS. Selective FTCWR is safe and has acceptable short‐term survival rates.
Circulating insulin-like growth factor system adaptations in hibernating brown bears indicate increased tissue IGF availability
Frøbert, Anne Mette , Brohus, Malene , Roesen, Tinna S., Kindberg, Jonas , Fröbert, Ole , Conover, Cheryl A. , Overgaard, Michael T.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | July 13, 2022 | Volume: 323 | Issue: 3 | Pages: E307-E318

10.1152/ajpendo.00429.2021 | PMID 35830688 Get It

Brown bears shift from circulating ternary IGF/IGFBP/ALS complexes in the active state to binary IGF/IGFBP complexes during hibernation, indicating increased tissue IGF-bioactivity. Furthermore, brown bears use a splice variant of IGF-2, suggesting increased bone-specific targeting of IGF anabolic signaling.
Generation of Cross‐Specialty Consensus Statements on Soft Tissue Management via a Modified Delphi Method
Matic, Damir B., Harder, Yves , Lettieri, Salvatore C. , Chen, Maio , Cheng, Joseph S. , Gauthier, Olivier , Chatterjee, Sandipan , Volgas, David A.

Mayo Clinic

World Journal of Surgery | July 13, 2022 | Volume: 46 | Issue: 9 | Pages: 2174-2188

10.1007/s00268-022-06627-5 | PMID 35831713 Get It

AbstractBackgroundSoft tissue management (STM) training programs for surgeons are largely tradition based, and substantial differences exist among different surgical specialties. The lack of comprehensive and systematic clinical evidence on how surgical techniques and implants affect soft tissue healing makes it difficult to develop evidence‐based curricula. As a curriculum development group (CDG), we set out to find common grounds in the form of a set of consensus statements to serve as the basis for surgical soft tissue education.MethodsFollowing a backward planning process and Kern's six‐step approach, the group selected 13 topics to build a cross‐specialty STM curriculum. A set of statements based on the curriculum topics were generated by the CDG through discussions and a literature review of three topics. A modified Delphi process including one round of pilot voting through a face‐to‐face CDG meeting and two rounds of web‐based survey involving 22 panelists were utilized for the generation of consensus statements.ResultsSeventy‐one statements were evaluated, and 56 statements reached the 80% consensus for “can be taught as is.”ConclusionsUsing a modified Delphi method, a set of cross‐specialty consensus statements on soft tissue management were generated. These consensus statements can be used as a foundation for multi‐specialty surgical education. Similar methods that combine expert experience and clinical evidence can be used to develop specialty‐specific consensus on soft tissue handling.
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Mehren, Margaret von , Kane, John M. , Agulnik, Mark , Carr, Janai R. , Connelly, Mary, Ganjoo, Kristen N. , Holder, Ashley M. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Mesko, Nathan W. , Meyer, Christian F. , Pappo, Alberto S. , Petersen, Ivy A. , Poppe, Matthew M. , Riedel, Richard F. , Schuetze, Scott M. , Shabason, Jacob E. , Zimel, Melissa N. , Hang, Lisa E., Sundar, Hema, Bergman, Mary Anne, Riedel, Richard F , von Mehren, Margaret , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , González, Ricardo , Liebner, David A. , Parkes, Amanda , Pollack, Seth M. , Sicklick, Jason Keith , Spraker, Matthew B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 13, 2022 | Volume: 20 | Issue: 7 | Pages: 815-833

10.6004/jnccn.2022.0035 | PMID 35830886 Get It

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.